FAROFLY™ 200

Faropenem is the only oral penem antibiotic currently available — a class closely related to carbapenems that occupies a unique pharmacological position as the oral agent with the broadest beta-lactam spectrum available without parenteral administration.

Like all beta-lactams, faropenem acts by binding to penicillin-binding proteins (PBPs) and inhibiting the transpeptidation step of peptidoglycan synthesis — causing structural failure of the bacterial cell wall, osmotic instability, and bacterial lysis. However, faropenem's specific PBP binding profile and its penem ring structure confer several advantages over conventional penicillins and cephalosporins:

Exceptional beta-lactamase stability: Faropenem's penem ring geometry makes it highly resistant to hydrolysis by most class A, C, and D beta-lactamases — including extended-spectrum beta-lactamases (ESBLs) that inactivate third and fourth-generation cephalosporins. This stability is the cornerstone of faropenem's clinical value in an era of increasing ESBL prevalence.

Broad spectrum: Faropenem covers gram-positive organisms (MSSA, S. pneumoniae including penicillin-resistant strains, streptococci) AND gram-negative organisms (E. coli, Klebsiella, H. influenzae, M. catarrhalis, Proteus, Moraxella) AND anaerobes (Bacteroides fragilis group, Peptostreptococcus) — a spectrum approaching that of parenteral carbapenems, delivered orally.

Oral delivery: Faropenem sodium achieves approximately 70–80% oral bioavailability, enabling the broad antimicrobial spectrum of carbapenem-class antibiotics to be delivered without intravenous access — a transformative pharmacological achievement for outpatient management of complex infections.

At 200mg per tablet with a 2-year expiry, FAROFLY™ 200 provides the oral penem option for moderate infections where standard oral antibiotics have failed or where ESBL-producing organisms are suspected.

FAROFLY™ 200 is indicated for moderate bacterial infections caused by resistant organisms or where broad-spectrum coverage — including ESBL-producing gram-negative bacteria and anaerobes — is required without parenteral therapy.

Community-Acquired Pneumonia (Resistant Pathogens): Pneumonia caused by penicillin-resistant S. pneumoniae, beta-lactamase-producing H. influenzae, or atypical organisms unresponsive to standard therapy. Faropenem's broad spectrum enables oral management of pneumonia cases that would otherwise require hospitalisation for IV antibiotics.

Paediatric ENT Infections (Recurrent/Resistant): Recurrent acute otitis media, sinusitis, and pharyngitis unresponsive to amoxycillin-clavulanate or standard cephalosporins — often involving ESBL-producing H. influenzae or multi-drug-resistant S. pneumoniae.

Urinary Tract Infections (ESBL): Uncomplicated and complicated UTIs caused by ESBL-producing E. coli and Klebsiella pneumoniae — a growing clinical challenge in India where ESBL prevalence exceeds 50% in many community-acquired UTI isolates.

Skin and Soft Tissue Infections: Moderate cellulitis and wound infections involving mixed aerobic-anaerobic flora or resistant gram-negative organisms.

Step-Down from Carbapenem: Oral faropenem as step-down therapy following initial parenteral carbapenem treatment, enabling safe and effective hospital-to-home transition.

Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.